Lonza concludes divestment of peptides business and operations
Facility in Braine-l’Alleud sold to PolyPeptide
Lonza has concluded the divestment of its peptides Business located in Braine-l’Alleud, (BE) to PolyPeptide Laboratories Holding (PPL). The facility, with approximately 280 employees, was the center for peptide chemical development and manufacturing within Lonza. The intention to divest was announced at the beginning of December 2016.
PolyPeptide Group announced that the harmonization of procedures at the Belgian facility to ensure consistency, continuity and quality within its expanded Group will be implemented in the coming months. The integration process is expected to be seamless to customers.
The financial terms of the transaction are not disclosed. As announced early December, Lonza has booked a non-cash related write-off of CHF 44 million. Furthermore, Lonza will also book a CHF 29 million non-cash currency translation impact in the first half of 2017.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.